冠状动脉支架术后按P2Y12抑制剂类型分层的P2Y12抑制剂单药治疗
本研究为SMART-CHOICE随机试验的预设分析,在2993例韩国成功置入药物洗脱支架的患者中,按所用P2Y12抑制剂类型比较3个月DAPT后P2Y12抑制剂单药治疗与12个月DAPT。结果显示,氯吡格雷使用者两种策略的主要终点无显著差异,强效P2Y12抑制剂使用者单药治疗出血更少。
要点
- 氯吡格雷使用者中,3个月DAPT后单药治疗与12个月DAPT的主要终点发生率均为3.0%,无显著差异。
- 强效P2Y12抑制剂使用者中,单药治疗组出血(BARC 2-5型)显著低于DAPT组(1.5% vs 5.0%)。
- 结论提示PCI术后氯吡格雷单药治疗的心血管结局与12个月DAPT相当。
核心结论
- 与12个月DAPT相比,氯吡格雷单药治疗在PCI术后患者中显示出相当的心血管结局。
- 在强效P2Y12抑制剂使用者中,单药治疗组出血事件显著少于DAPT组,但主要终点差异无统计学意义。
研究设计与样本
- SMART-CHOICE随机试验的预设分析,比较3个月DAPT后P2Y12抑制剂单药治疗与12个月DAPT。
- 共纳入2993例在韩国成功接受药物洗脱支架PCI的患者,按氯吡格雷(2312例,77.2%)或强效P2Y12抑制剂(681例,22.8%)分层比较。
- 主要终点为术后12个月全因死亡、心肌梗死或卒中的复合终点。
主要发现
- 氯吡格雷组主要终点:单药治疗3.0% vs DAPT 3.0%(HR 1.02;95%CI 0.64-1.65;p=0.93)。
- 强效P2Y12抑制剂组主要终点:单药治疗2.4% vs DAPT 0.7%(HR 3.37;95%CI 0.77-14.78;p=0.11;交互p=0.1)。
- 强效P2Y12抑制剂组出血(BARC 2-5型):单药治疗1.5% vs DAPT 5.0%(HR 0.33;95%CI 0.12-0.87;p=0.03)。
- 氯吡格雷组单药治疗与DAPT在各亚组的主要终点治疗效果一致。
临床怎么用
- PCI术后接受氯吡格雷治疗的患者,可考虑3个月DAPT后转为P2Y12抑制剂单药治疗。
- 使用强效P2Y12抑制剂者转为单药治疗需权衡缺血与出血风险,本研究提示出血减少但主要终点差异未达统计学意义。
局限性
- 本研究为预设亚组分析,强效P2Y12抑制剂组样本量较小(681例),事件数有限。
- 研究在韩国单一人群开展,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare P2Y12 inhibitor monotherapy after 3-month dual antiplatelet therapy (DAPT) with 12-month DAPT according to the type of P2Y12 inhibitor in patients undergoing percutaneous coronary intervention (PCI). METHODS: The Smart Angioplasty Research Team: Comparison Between P2Y12 Antagonist Monotherapy vs Dual Antiplatelet Therapy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents (SMART-CHOICE) randomised trial compared 3-month DAPT followed by P2Y12 inhibitor monotherapy with 12-month DAPT. In this trial, 2993 patients undergoing successful PCI with drug-eluting stent were enrolled in Korea. As a prespecified analysis, P2Y12 inhibitor monotherapy after 3-month DAPT versus 12-month DAPT were compared among patients receiving clopidogrel and those receiving potent P2Y12 inhibitor (ticagrelor or prasugrel), respectively. The primary endpoint was a composite of all-cause death, myocardial infarction or stroke at 12 months after the index procedure. RESULTS: Among 2993 patients (mean age 64 years), 58.2% presented with acute coronary syndrome. Clopidogrel was prescribed in 2312 patients (77.2%) and a potent P2Y12 inhibitor in 681 (22.8%). There were no significant differences in the primary endpoint between the P2Y12 inhibitor monotherapy group and the DAPT group among patients receiving clopidogrel (3.0% vs 3.0%; HR: 1.02; 95% CI 0.64 to 1.65; p=0.93) as well as among patients receiving potent P2Y12 inhibitors (2.4% vs 0.7%; HR: 3.37; 95% CI 0.77 to 14.78; p=0.11; interaction p=0.1). Among patients receiving clopidogrel, P2Y12 inhibitor monotherapy compared with DAPT showed consistent treatment effects across various subgroups for the primary endpoint. Among patients receiving potent P2Y12 inhibitors, the rate of bleeding (Bleeding Academic Research Consortium types 2- 5) was significantly lower in the P2Y12 inhibitor monotherapy group than in the DAPT group (1.5% vs 5.0%; HR: 0.33; 95% CI 0.12 to 0.87; p=0.03). CONCLUSIONS: Compared with 12-month DAPT, clopidogrel monotherapy after 3-month DAPT showed comparable cardiovascular outcomes in patients undergoing PCI. TRIAL REGISTRATION NUMBER: NCT02079194.
引用
- Kim J, Jang WJ, Lee WS, et al. P2Y12 inhibitor monotherapy after coronary stenting according to type of P2Y12 inhibitor. Heart. 2021. PMID: 33758008. doi:10.1136/heartjnl-2020-318821
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。